Acarix Recognized as 2025 Digital Innovation Winner in Cardiac Care

Acarix Triumphs at the Global Cardiovascular Awards 2025

Acarix, a renowned leader in AI and acoustics-based cardiac diagnostics, has achieved significant recognition at the Global Cardiovascular Awards held in London. The company was awarded the prestigious 2025 Digital Innovation Award and received an honorable mention for its exceptional contributions to cardiac imaging with its innovative CADScor® System.

The Digital Innovation Award celebrates the use of groundbreaking digital, mobile, and AI technologies that are reshaping cardiovascular care. Acarix’s CADScor System exemplifies this revolution in early cardiac diagnostics. By providing a non-invasive, AI-driven approach, the system allows for rapid and accurate assessment of coronary artery disease (CAD). This empowers healthcare professionals to identify patients with stable chest pain promptly, ensuring they receive the necessary evaluations without unnecessary procedures.

Aamir Mahmood, President and CEO of Acarix, expressed his pride in this achievement. He stated, "It is an honor to be acknowledged among the innovators advancing cardiovascular care globally. The Digital Innovation Award and the honorable mention for Innovation in Cardiac Imaging are testaments to our commitment to improving patient outcomes through advanced technology."

The CADScor System is designed to deliver impressive results, achieving over 96% certainty in low-risk stratification. This ability significantly reduces the need for invasive and costly diagnostic procedures, ultimately streamlining patient care pathways. Mahmood emphasized that this innovation is a game-changer for both patients and healthcare providers, enhancing the quality and efficiency of medical assessments.

The Global Cardiovascular Awards are determined by a distinguished panel comprised of international experts, including CEOs, clinical leaders, and key opinion leaders in the cardiovascular fields. These experts conduct a meticulous evaluation of innovations that exhibit tangible impacts on cardiovascular health globally. The awards aim to highlight those at the forefront of revolutionizing cardiovascular care.

Founded to illuminate the future of cardiovascular care, the Global Cardiovascular Awards celebrate outstanding contributions from researchers, clinicians, innovators, and organizations dedicated to enhancing prevention, diagnosis, and treatment of cardiovascular diseases.

Acarix itself is a Swedish medical device company focused on pioneering innovative solutions for early risk assessment of coronary artery disease at the point of care. The CADScor System, which is CE-marked and FDA De Novo-cleared, caters specifically to patients experiencing chest pain with suspected CAD. By significantly reducing unnecessary and invasive diagnostics, the device has already been utilized for over 40,000 patients, indicating its effectiveness and reliability. The system employs advanced computational analysis and highly sensitive acoustic detection to assess coronary blood flow, enabling healthcare providers to rule out significant CAD with high certainty.

Acarix is publicly traded on the Nasdaq First North Premier Growth Market in Stockholm under the ticker symbol ACARIX and is also available on the OTCQB market in the U.S. with the ticker ACIXF. With its innovative approach, Acarix continues to lead the way in transforming cardiac diagnostics and improving patient outcomes in cardiovascular care.

For further information, visit Acarix's official website.